Structure Therapeutics (GPCR) isn’t a well-known weight loss treatment stock just yet. But it may soon be. According to JPMorgan, it’s an overlooked player in the weight loss treatment market. The firm has an overweight rating on the stock, with a price target of $65.
“We think the opportunity for oral GLP-1s is underappreciated and think this market could generate $30bn in sales by 2035,” added the firm, as quoted by CNBC. “GPCRs lead asset, 1290, is a pure-play option for this opportunity, and even a small share would support substantial upside to the stock.”
Better, its addressable market is substantial. According to the World Obesity Federation, “In its World Obesity Atlas 2023, the federation said the economic impact of overweight and obesity on the world is set to reach $4.32tn—nearly 3% of global gross domestic product.”